Dr. Michael S. Thakor, MD
Rheumatology (Rheumatology Physician)
2121 E Harmony Rd, Ste 361
Fort Collins, CO 80528
Who else practices at this address →
Larimer County includes primary care (0% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Creighton University School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 984
Licensed in Colorado since 2002, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: Creighton University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
CO license 40814 (first issued 2002; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Poudre Valley Hospital Fort Collins, CO
- Medical Center of the Rockies Loveland, CO
- Cheyenne Regional Medical Center Cheyenne, WY
- Regional West Medical Center Scottsbluff, NE
- Ivinson Memorial Hospital Laramie, WY
Medical groups
- Select Physical Therapy of West Denver Limited PArtnership (548 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 984
- Services billed
- 159,362
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, tocilizumab, 1 mg | 49,121 | 15 |
| Injection, infliximab, excludes biosimilar, 10 mg | 18,880 | 57 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 15,975 | 24 |
| Injection, denosumab, 1 mg | 4,500 | 44 |
| Injection, rituximab, 10 mg | 3,850 | 15 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,643 | 845 |
| Administration of chemotherapy into vein, 1 hour or less | 580 | 92 |
| Administration of chemotherapy into vein, each additional hour | 522 | 73 |
| Established patient office or other outpatient visit, 30-39 minutes | 364 | 246 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 352 | 57 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $35.00 in total to this clinician.
| Merck Sharp & Dohme LLC | $35.00 |
|---|
| Food and Beverage | $35.00 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 22 industry-funded studies in 2025, from 7 companies. The companies reported $1,001,353 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
ModernaTX, Inc. · Completed · NCT05575492 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity
Amgen Inc. - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited - A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
AbbVie Inc. · Recruiting · NCT06972446 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
AbbVie Inc. · Completed · NCT05814627 - Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patie…
Argenx US, Inc. - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS)
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.